Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

被引：0

作者：

Wolfgang Mueck

Bengt I. Eriksson

Kenneth A. Bauer

Lars Borris

Ola E. Dahl

William D. Fisher

Michael Gent

Sylvia Haas

Menno V. Huisman

Ajay K. Kakkar

Peter Kälebo

Louis M. Kwong

Frank Misselwitz

Alexander G. G. Turpie

机构：

[1] Bayer HealthCare AG,Department of Medicine

[2] Sahlgrenska University Hospital/Östra,Clinical Pharmacology

[3] Beth Israel Deaconess Medical Center,undefined

[4] Aarhus University Hospital,undefined

[5] Thrombosis Research Institute,undefined

[6] McGill University Health Centre,undefined

[7] HHS-General Hospital,undefined

[8] Institute for Experimental Oncology and Therapy Research,undefined

[9] Leiden University Medical Center,undefined

[10] Barts and the London School of Medicine,undefined

[11] Harbor-UCLA Medical Center,undefined

[12] Bayer Health-Care AG,undefined

来源：

Clinical Pharmacokinetics | 2008年 / 47卷

关键词：

Enoxaparin; Rivaroxaban; Objective Function Value; Predictable Pharmacokinetic; International Sensitivity Index;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. This analysis was performed to characterize the population pharmacokinetics and pharmacodynamics of rivaroxaban in patients participating in two phase II, double-blind, randomized, active-comparator-controlled studies of twice-daily rivaroxaban for the prevention of venous thromboembolism after total hip- or knee-replacement surgery.

引用

页码：203 / 216

页数：13

共 61 条

[1]

Ansell J.(2004)Current options in the prevention of thromboembolic disease Drugs 64 1-5

[2]

Bergqvist D.(2005)Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 412-21

[3]

Kubitza D.(2005)Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 — an oral, direct Factor Xa inhibitor — after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 873-80

[4]

Becka M.(2007)Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects J Clin Pharmacol 47 218-26

[5]

Voith B.(2006)Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban — an oral, direct Factor Xa inhibitor — are not affected by aspirin J Clin Pharmacol 46 981-90

[6]

Kubitza D.(2007)Rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor — has no clinically relevant interaction with naproxen Br J Clin Pharmacol 63 469-76

[7]

Becka M.(2006)No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin [abstract no. 11] J Clin Pharmacol 46 702-25

[8]

Wensing G.(2004)Orthopaedic surgery as a model for drug development in thrombosis Drugs 64 17-86

[9]

Kubitza D.(2005)BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study J Thromb Haemost 3 2479-8

[10]

Becka M.(2006)Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement J Thromb Haemost 4 121-81

← 1 2 3 4 5 6 7 →